- Home
- CELZ vs INAB Comparison
CELZ vs INAB Comparison
Compare CELZ & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- INAB
- Stock Information
- Founded
- CELZ 1998
- INAB 2016
- Country
- CELZ United States
- INAB United States
- Employees
- CELZ N/A
- INAB N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- INAB Health Care
- Exchange
- CELZ Nasdaq
- INAB Nasdaq
- Market Cap
- CELZ 10.4M
- INAB 10.6M
- IPO Year
- CELZ N/A
- INAB 2021
- Fundamental
- Price
- CELZ $3.09
- INAB $1.63
- Analyst Decision
- CELZ
- INAB Strong Buy
- Analyst Count
- CELZ 0
- INAB 2
- Target Price
- CELZ N/A
- INAB $108.00
- AVG Volume (30 Days)
- CELZ 169.9K
- INAB 72.9K
- Earning Date
- CELZ 11-07-2025
- INAB 11-06-2025
- Dividend Yield
- CELZ N/A
- INAB N/A
- EPS Growth
- CELZ N/A
- INAB N/A
- EPS
- CELZ N/A
- INAB N/A
- Revenue
- CELZ $6,000.00
- INAB N/A
- Revenue This Year
- CELZ N/A
- INAB N/A
- Revenue Next Year
- CELZ N/A
- INAB N/A
- P/E Ratio
- CELZ N/A
- INAB N/A
- Revenue Growth
- CELZ N/A
- INAB N/A
- 52 Week Low
- CELZ $1.69
- INAB $1.53
- 52 Week High
- CELZ $6.90
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- CELZ 45.24
- INAB 32.35
- Support Level
- CELZ $2.77
- INAB $1.53
- Resistance Level
- CELZ $3.34
- INAB $1.77
- Average True Range (ATR)
- CELZ 0.47
- INAB 0.17
- MACD
- CELZ -0.05
- INAB -0.02
- Stochastic Oscillator
- CELZ 17.24
- INAB 12.28
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.